Drug Trial Radar · NCT02496221
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jun 11, 2015
Primary completion
Oct 13, 2015
Study completion Oct 13, 2015
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 14, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus. The primary objective of this study is to assess if a single dose of albiglutide can affect cholecystokinin-induced gallbladder emptying. To make this assessment, each study participant will receive a dose of albiglutide and a dose of placebo followed by cholecystokinin (CCK) infusion and ultrasound measurement of the gallbladder. The study will be comprised of two periods and 20 subjects. The screening visit will occur within 42 days of the start of Treatment Period 1. The Treatment Periods will be separated by a washout period of a minimum of 42 days. Subjects will return for a follow-up visit after 28 days following the last dose of albiglutide or placebo. The total duration of a subject's participation from Screening to Follow-up will be approximately 17.5 weeks. This study is a post marketing commitment to the United States Food and Drug Administration (USFDA).
Conditions
- Diabetes Mellitus, Type 2
Interventions
Albiglutide 50 mgDrug
Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
PlaceboDrug
Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
CCK (Kinevac)Drug
CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Absolute Value of Gallbladder Ejection Fraction (Emax GEF) During Cholecystokinin (CCK) Infusion, as a Measure of Maximum EffectTime frame: Day 4 in each treatment period
- Area Under the Effect Curve for Gallbladder Ejection Fraction (AUEC GEF)Time frame: Day 4 in each treatment period
- Time at Which the Maximum Effect (Emax GEF) Occurred (TEMAXEF) During the CCK InfusionTime frame: Day 4 in each treatment period
- Maximum Gallbladder Ejection Fraction Value During CCK InfusionTime frame: Day 1 and Day 4 in each treatment period
- Area Under the Effect Curve for Gallbladder Volume (AUEC VL)Time frame: Day 4 in each treatment period
- Maximum Absolute Change From Baseline in Value of Gallbladder Volume (Emax VL) During CCK Infusion, as a Measure of Maximum EffectTime frame: Day 4 in each treatment period
- Time at Which the Maximum Effect (Emax VL) Occurred (TEmax VL) During the CCK InfusionTime frame: Day 4 in each treatment period
- Maximum Change From Baseline in Main Pancreatic Duct Diameter During CCK InfusionTime frame: Day 4 in each treatment period
- Maximum Change From Baseline in Common Bile Duct Diameter During CCK InfusionTime frame: Day 4 in each treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.